The chemotherapy given before CAR T-cell therapy can cause brain inflammation and memory problems on its own, meaning some cognitive side effects may be due to the preparatory drugs, not the CAR T-cells.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether cognitive impairment after CAR T-cell therapy is more severe in patients who received lymphodepleting chemotherapy compared to those who did not.
A systematic review and meta-analysis of all clinical studies comparing cognitive outcomes in patients receiving CAR T-cell therapy with and without prior lymphodepletion (fludarabine/cyclophosphamide), using standardized neuropsychological batteries and controlling for tumor type, age, and prior therapies.
Whether omitting lymphodepleting chemotherapy reduces cognitive impairment in patients receiving CAR T-cell therapy.
A double-blind, randomized trial of 120 patients with relapsed B-cell malignancies, randomized to receive CAR T-cell therapy with or without fludarabine/cyclophosphamide lymphodepletion, with cognitive testing at baseline, 1, 3, and 6 months, and CSF biomarkers for neuroinflammation.
Whether the intensity of lymphodepleting chemotherapy correlates with the severity of cognitive decline in CAR T-cell therapy recipients.
A prospective cohort study of 600 CAR T-cell therapy recipients, stratified by lymphodepletion regimen (e.g., standard vs. reduced dose), with annual cognitive assessments and CSF biomarkers for microglial activation and oligodendrocyte integrity over 5 years.
Whether patients with CAR T-cell therapy-related cognitive impairment have received more intensive lymphodepletion than those without impairment.
A case-control study comparing the cumulative dose of fludarabine and cyclophosphamide in 100 CAR T recipients with cognitive impairment (MoCA <24) to 100 matched controls without impairment, adjusting for age, tumor type, and prior therapies.
Whether cognitive performance in CAR T-cell therapy survivors correlates with the intensity of prior lymphodepleting chemotherapy.
A cross-sectional study of 350 CAR T-cell therapy survivors comparing cognitive test scores with cumulative doses of fludarabine and cyclophosphamide received prior to CAR T-cell therapy, adjusting for time since therapy and age.